R
Romosozumab
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Subsidy Information and Financing Scheme
No
Active ingredient: Romosozumab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
04/06/2025 Romosozumab and teriparatide for treating osteoporosis
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended:
Romosozumab or teriparatide reference biologic (Forteo) for inclusion on the MOH List of Subsidised Drugs for treating postmenopausal women with osteoporosis who are at high risk for fracture; and
Teriparatide reference biologic (Forteo) for inclusion on the MOH List of Subsidised Drugs for treating men with primary or hypogonadal osteoporosis who are at high risk for fracture, or patients with glucocorticoid-induced osteoporosis who are at high risk for fracture
due to uncertain extent of clinical benefit and unfavourable cost-effectiveness compared with subsidised alternatives.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Evenity Injection, Solution 105 mg/1.17 mL |
|